Research Protocol - Efficacy of Amodiaquine-Artesunate and Artemether-Lumefantrine for the Treatment of Uncomplicated Childhood Plasmodium falciparum Malaria

Hdl Handle:
http://hdl.handle.net/10144/322257
Title:
Research Protocol - Efficacy of Amodiaquine-Artesunate and Artemether-Lumefantrine for the Treatment of Uncomplicated Childhood Plasmodium falciparum Malaria
Authors:
de Wit, Marit; Bil, Karla; Piriou, Erwan; Siddiqui, Ruby; Bahizi Bizoza, Patrick; van Gool, Tom; Woolley, Ian
Abstract:
PRIMARY OBJECTIVES of study: To compare the in vivo efficacy of artesunate-amodiaquine (ASAQ) versus artemether-lumefantrine (CoartemĀ®) in a population of children aged between 6 and 59 months suffering from uncomplicated P. falciparum malaria. This will be expressed as the PCR genotyping corrected rates of parasite clearance as a measure of efficacy at day 42 after initiation of anti-malarial therapy (the correction is for recrudescence versus re-infection). This will provide the MoH with evidence for the most appropriate choice of ACT for this region. SECONDARY OBJECTIVES: - To measure the PCR uncorrected efficacy of both drugs at day 42 after treatment initiation - To measure the PCR corrected and uncorrected efficacy of both drugs at days 14 and 28 after treatment initiation - To calculate the proportion of early therapeutic failures, late clinical failures and late parasitological failures in a period of 42 days after treatment initiation - To formulate recommendations and to enable the Ministry of Health to make informed decisions about
Affiliation:
MSF-OCA; MSF-Holland; MSF-Holland; MSF-UK; Ministry of Health, South Kivu, DRC; Academic Medical Center, Holland; MSF-UK
Issue Date:
Jun-2014
URI:
http://hdl.handle.net/10144/322257
Type:
Other
Language:
en
Description:
Research protocol. These materials can be used, adapted and copied as long as citation of the source is given including the direct URL to the material. This work is licensed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0/ https://i.creativecommons.org/l/by/4.0/88x31.png
Appears in Collections:
MSF Research Protocols

Full metadata record

DC FieldValue Language
dc.contributor.authorde Wit, Marit; Bil, Karla; Piriou, Erwan; Siddiqui, Ruby; Bahizi Bizoza, Patrick; van Gool, Tom; Woolley, Ianen_GB
dc.date.accessioned2014-06-27T11:14:26Z-
dc.date.available2014-06-27T11:14:26Z-
dc.date.issued2014-06-
dc.identifier.urihttp://hdl.handle.net/10144/322257-
dc.descriptionResearch protocol. These materials can be used, adapted and copied as long as citation of the source is given including the direct URL to the material. This work is licensed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0/ https://i.creativecommons.org/l/by/4.0/88x31.pngen_GB
dc.description.abstractPRIMARY OBJECTIVES of study: To compare the in vivo efficacy of artesunate-amodiaquine (ASAQ) versus artemether-lumefantrine (CoartemĀ®) in a population of children aged between 6 and 59 months suffering from uncomplicated P. falciparum malaria. This will be expressed as the PCR genotyping corrected rates of parasite clearance as a measure of efficacy at day 42 after initiation of anti-malarial therapy (the correction is for recrudescence versus re-infection). This will provide the MoH with evidence for the most appropriate choice of ACT for this region. SECONDARY OBJECTIVES: - To measure the PCR uncorrected efficacy of both drugs at day 42 after treatment initiation - To measure the PCR corrected and uncorrected efficacy of both drugs at days 14 and 28 after treatment initiation - To calculate the proportion of early therapeutic failures, late clinical failures and late parasitological failures in a period of 42 days after treatment initiation - To formulate recommendations and to enable the Ministry of Health to make informed decisions abouten_GB
dc.language.isoenen
dc.subjectmalariaen_GB
dc.subjecttreatment efficacyen_GB
dc.titleResearch Protocol - Efficacy of Amodiaquine-Artesunate and Artemether-Lumefantrine for the Treatment of Uncomplicated Childhood Plasmodium falciparum Malariaen
dc.typeOtheren
dc.contributor.departmentMSF-OCA; MSF-Holland; MSF-Holland; MSF-UK; Ministry of Health, South Kivu, DRC; Academic Medical Center, Holland; MSF-UKen_GB
All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.